FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome

25 Mar 20264 min read0 views

GIST

The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).

Clinical Editorial

Summary

FDA News Releases published a clinical update in Research Highlights on 25 Mar 2026. The item focuses on FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome. Open the detail page to review the full original feed content.